Greenland Mines Ltd

Greenland Mines Ltd develops essential medicines for chronic diseases including cancer, cardiovascular, and neurodegenerative disorders, and also engages in the development and mining of critical and precious minerals. The company operates through two main platforms: a generic drug and biosimilar biologics platform, and a proprietary, patented gene therapy platform. The generic drug and biosimilar biologics platform includes biologic therapies for cancer. On September 12, 2022, Greenland Mines acquired five market-approved anti-cancer drugs for sale in Germany. These Market Authorizations cover four drugs used in the "FOLFOX" and "FOLFIRI" multi-drug regimens for metastatic colorectal and gastric cancer, and two drugs for metastatic lung cancer, which are important for treating solid tumors in both childhood and adult cancers. Previously, the company acquired two off-patent biogeneric antibodies from Reliance Life Sciences. The proprietary gene therapy platform uses a gene therapy approach to introduce a therapeutic protein called "Klotho" to treat neurodegenerative diseases. In March 2026, the company completed the acquisition of Greenland Mines Corp., expanding its operations into critical and precious mineral development and mining. Greenland Mines Ltd's Common Stock and Warrants trade on the Nasdaq under the symbols "GRML" and "GRMLW" respectively.